Tympulse Medical

200 million adults globally have preventable disabling hearing loss, predominantly due to burst eardrums. Current solution requires surgery which takes 2-3 hours and requires general anaesthetic, harvested donor tissue and a large incision behind ear.

Tympulse Medical’s first product, TympanoColl, is a new technology for the fast and effective repair of damaged tympanic membranes. TympanoColl is an exciting combination of a new collagen based biodegradable implant with an innovative single-step delivery system to repair the ear drum via the ear canal.

The product will be supplied as a complete ENT surgical toolkit, to complete the procedure quickly, easily and safely in an outpatient setting. Reduction of surgery time to ~30 minutes (compared to three hours with current surgical procedure). Serviceable addressable market (SAM) for EU, US and Aus/ME/Asia Pacific is 480,000 cases which equates to €421m.

Promoters

Current status

  • Completed EI Commercialisation Fund
  • In vivo proof of concept achieved
  • Patent filed
  • EI pre-seed start fund investment completed 2023

Next steps

  • Seed round – €2m
  • Set up small scale cGMP manufacturing site
  • ISO and QMS system approval
  • First-in-man [FIM] implantations

Watch the video here

Spin-out summary – Tympulse PDF | 428.7 KB